Chernock Rebecca D, Zhang Qin, El-Mofty Samir K, Thorstad Wade L, Lewis James S
Department of Pathology and Immunology, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8118, St Louis, MO 63110, USA.
Arch Otolaryngol Head Neck Surg. 2011 Feb;137(2):163-9. doi: 10.1001/archoto.2010.246.
To evaluate the frequency of human papillomavirus-related oropharyngeal squamous cell carcinoma in African Americans and whites and to examine patient outcomes in these 2 groups.
Retrospective study.
One tertiary care, university medical center.
Information on patients with stage III/IV oropharyngeal squamous cell carcinoma diagnosed between 1998 and 2007, and with primary surgical samples available for review, were selected from a radiotherapy database. One patient was Native American and was excluded from analysis; data on 174 patients were analyzed.
One hundred forty-eight patients (85.1%) were white and 26 (14.9%) were African American. Human papillomavirus in situ hybridization-positive and p16-positive tumors were much more common in whites (63.5% and 83.1% of tumors, respectively) than in African Americans (11.5% and 34.6% of tumors, respectively) (P < .001). African Americans were also more likely to have received definitive (nonsurgical) rather than postoperative radiation therapy (P = .001) and had a higher frequency of T3/T4-stage tumors (P = .03) compared with whites. Disease-free survival was significantly shorter for African Americans (P = .02). In multivariate analysis, viral status (P = .006), T stage (P = .02), and treatment type (P = .002), but not race (P = .98), were significant factors contributing to disease-free survival.
In high-stage oropharyngeal squamous cell carcinoma, the proportion of human papillomavirus-related tumors is much higher in whites than in African Americans. African Americans also appear to develop higher T-stage tumors and are more likely to receive definitive therapy. The shorter disease-free survival observed in African Americans may be due to viral status, treatment type, and higher T stage, but does not appear to be due to race.
评估非裔美国人和白人中与人乳头瘤病毒相关的口咽鳞状细胞癌的发生率,并研究这两组患者的预后情况。
回顾性研究。
一家三级医疗大学医学中心。
从放疗数据库中选取1998年至2007年间诊断为III/IV期口咽鳞状细胞癌且有原发性手术样本可供复查的患者信息。有1名患者为美国原住民,被排除在分析之外;对174名患者的数据进行了分析。
148名患者(85.1%)为白人,26名患者(14.9%)为非裔美国人。人乳头瘤病毒原位杂交阳性和p16阳性肿瘤在白人中(分别占肿瘤的63.5%和83.1%)比在非裔美国人中(分别占肿瘤的11.5%和34.6%)更为常见(P <.001)。与白人相比,非裔美国人也更有可能接受根治性(非手术)而非术后放射治疗(P =.001),且T3/T4期肿瘤的发生率更高(P =.03)。非裔美国人的无病生存期明显较短(P =.02)。在多变量分析中,病毒状态(P =.006)、T分期(P =.02)和治疗类型(P =.002),而非种族(P =.98),是影响无病生存期的重要因素。
在晚期口咽鳞状细胞癌中,与人乳头瘤病毒相关的肿瘤比例在白人中比在非裔美国人中高得多。非裔美国人似乎也更容易发生T分期较高的肿瘤,并且更有可能接受根治性治疗。在非裔美国人中观察到的较短无病生存期可能归因于病毒状态、治疗类型和较高的T分期,但似乎并非由种族所致。